71 results
SC TO-T
EX-99
BMY
Bristol-Myers Squibb Co.
25 Jan 24
Third party tender offer statement
8:13am
participants in the industries in which RayzeBio operates or the economy generally, as applicable; (vi) any epidemic, pandemic (including COVID-19
424B5
BMY
Bristol-Myers Squibb Co.
1 Nov 23
Prospectus supplement for primary offering
4:16pm
pandemic on our operations; the risk that the approval of Mirati’s stockholders with respect to our proposed acquisition of Mirati may be delayed or may
424B3
BMY
Bristol-Myers Squibb Co.
30 Oct 23
Prospectus supplement
8:05am
of new or revised accounting standards; risks relating to public health outbreaks, epidemics and pandemics, including the impact of the COVID-19 pandemic
8-K
EX-99.1
93q5ew
26 Oct 23
Bristol Myers Squibb Reports Third Quarter Financial Results for 2023
7:44am
8-K
EX-99.1
07i9yra3ilrgd0
27 Jul 23
Bristol Myers Squibb Reports Second Quarter Financial Results for 2023
7:50am
8-K
EX-99.1
2k74i881i 0ueq4g4
27 Apr 23
Bristol Myers Squibb Reports First Quarter Financial Results for 2023
7:45am
8-K
EX-99.1
1h79i
26 Oct 22
Bristol Myers Squibb Reports Third Quarter Financial Results for 2022
7:48am
8-K
EX-99.1
0127at
27 Jul 22
Bristol Myers Squibb Reports Second Quarter Financial Results for 2022
7:44am
SC TO-T
EX-99
k9wq1r
17 Jun 22
Third party tender offer statement
4:42pm
8-K
EX-99.1
vn24 ycmc
29 Apr 22
Bristol Myers Squibb Reports First Quarter Financial Results for 2022
7:42am
8-K
EX-99.2
5ky3ccrqw8fomfsy
3 Mar 22
Upsizing and Early Settlement of Tender Offers
4:16pm